<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34439911</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1246</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom11081246</ELocationID><Abstract><AbstractText>The urgent need for new therapies for some devastating neuromuscular diseases (NMDs), such as Duchenne muscular dystrophy or amyotrophic lateral sclerosis, has led to an intense search for new potential biomarkers. Biomarkers can be classified based on their clinical value into different categories: diagnostic biomarkers confirm the presence of a specific disease, prognostic biomarkers provide information about disease course, and therapeutic biomarkers are designed to predict or measure treatment response. Circulating biomarkers, as opposed to instrumental/invasive ones (e.g., muscle MRI or nerve ultrasound, muscle or nerve biopsy), are generally easier to access and less "time-consuming". In addition to well-known creatine kinase, other promising molecules seem to be candidate biomarkers to improve the diagnosis, prognosis and prediction of therapeutic response, such as antibodies, neurofilaments, and microRNAs. However, there are some criticalities that can complicate their application: variability during the day, stability, and reliable performance metrics (e.g., accuracy, precision and reproducibility) across laboratories. In the present review, we discuss the application of biochemical biomarkers (both validated and emerging) in the most common NMDs with a focus on their diagnostic, prognostic/predictive and therapeutic application, and finally, we address the critical issues in the introduction of new biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barp</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8015-2597</Identifier><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO) Trento, Villa Rosa Hospital, Via Spolverine 84, 38057 Pergine Valsugana, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrero</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO) Trento, Villa Rosa Hospital, Via Spolverine 84, 38057 Pergine Valsugana, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casagrande</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4111-1810</Identifier><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO) Trento, Villa Rosa Hospital, Via Spolverine 84, 38057 Pergine Valsugana, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Drug and Child Health, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morini</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4012-8175</Identifier><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO) Trento, Villa Rosa Hospital, Via Spolverine 84, 38057 Pergine Valsugana, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuccarino</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NeuroMuscular Omnicentre (NeMO) Trento, Villa Rosa Hospital, Via Spolverine 84, 38057 Pergine Valsugana, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020388" MajorTopicYN="N">Muscular Dystrophy, Duchenne</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009468" MajorTopicYN="N">Neuromuscular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">creatine kinase</Keyword><Keyword MajorTopicYN="N">microRNA</Keyword><Keyword MajorTopicYN="N">neurofilament</Keyword><Keyword MajorTopicYN="N">neuromuscular disease</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34439911</ArticleId><ArticleId IdType="pmc">PMC8393752</ArticleId><ArticleId IdType="doi">10.3390/biom11081246</ArticleId><ArticleId IdType="pii">biom11081246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aartsma-Rus A., Ferlini A., McNally E.M., Spitali P., Sweeney H.L., Aartsma-Rus A.M., Szigyarto C.A.-K., Bello L., Bronson A., Brown K., et al. 226th ENMC International Workshop: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands. Neuromuscul. Disord. 2018;28:77&#x2013;86. doi: 10.1016/j.nmd.2017.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2017.10.002</ArticleId><ArticleId IdType="pmc">PMC5957286</ArticleId><ArticleId IdType="pubmed">29203356</ArticleId></ArticleIdList></Reference><Reference><Citation>Aartsma-Rus A., Ferlini A., Vroom E. Biomarkers and surrogate endpoints in Duchenne: Meeting report. Neuromuscul. Disord. 2014;24:743&#x2013;745. doi: 10.1016/j.nmd.2014.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2014.03.006</ArticleId><ArticleId IdType="pubmed">24951452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve. 2013;48:21&#x2013;26. doi: 10.1002/mus.23810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23810</ArticleId><ArticleId IdType="pubmed">23716304</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel B.L., Cox D., Barbieri M., Ziemba M., Straub V., Hoffman E.P., Russell A.J. Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy. Muscle Nerve. 2021;64:43&#x2013;49. doi: 10.1002/mus.27222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27222</ArticleId><ArticleId IdType="pmc">PMC8362156</ArticleId><ArticleId IdType="pubmed">33683712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaharieva I.T., Calissano M., Scoto M., Preston M.D., Cirak S., Feng L., Collins J., Kole R., Guglieri M., Straub V., et al. Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy. PLoS ONE. 2013;8:e80263. doi: 10.1371/journal.pone.0080263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0080263</ArticleId><ArticleId IdType="pmc">PMC3840009</ArticleId><ArticleId IdType="pubmed">24282529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacchiarelli D., Legnini I., Martone J., Cazzella V., D&#x2019;Amico A., Bertini E., Bozzoni I. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol. Med. 2011;3:258&#x2013;265. doi: 10.1002/emmm.201100133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201100133</ArticleId><ArticleId IdType="pmc">PMC3112257</ArticleId><ArticleId IdType="pubmed">21425469</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts T.C., Blomberg K.E.M., McClorey G., EL Andaloussi S., Godfrey C., Betts C., Coursindel T., Gait M.J., Smith C.I.E., Wood M.J. Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy. Mol. Ther. Nucleic Acids. 2012;1:e39. doi: 10.1038/mtna.2012.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2012.26</ArticleId><ArticleId IdType="pmc">PMC3437806</ArticleId><ArticleId IdType="pubmed">23344181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzella V., Martone J., Pinnar&#xf2; C., Santini T., Twayana S.S., Sthandier O., D&#x2019;Amico A., Ricotti V., Bertini E., Muntoni F., et al. Exon 45 Skipping Through U1-snRNA Antisense Molecules Recovers the Dys-nNOS Pathway and Muscle Differentiation in Human DMD Myoblasts. Mol. Ther. 2012;20:2134&#x2013;2142. doi: 10.1038/mt.2012.178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2012.178</ArticleId><ArticleId IdType="pmc">PMC3498801</ArticleId><ArticleId IdType="pubmed">22968481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim G.A., Zweber B.A., Awad E.A. Muscle and serum enzymes and isoenzymes in muscular dystrophies. Arch. Phys. Med. Rehabilitation. 1981;62:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">7235920</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegoraro V., Angelini C. Circulating miR-206 as a Biomarker for Patients Affected by Severe Limb Girdle Muscle Dystrophies. Genes. 2021;12:85. doi: 10.3390/genes12010085.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12010085</ArticleId><ArticleId IdType="pmc">PMC7826967</ArticleId><ArticleId IdType="pubmed">33445560</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsoulidou A., Kyriakides T.C., Papadimas G.K., Christou Y., Kararizou E., Papanicolaou E.Z., Phylactou L.A. Elevated Muscle-Specific miRNAs in Serum of Myotonic Dystrophy Patients Relate to Muscle Disease Progress. PLoS ONE. 2015;10:e0125341. doi: 10.1371/journal.pone.0125341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0125341</ArticleId><ArticleId IdType="pmc">PMC4411125</ArticleId><ArticleId IdType="pubmed">25915631</ArticleId></ArticleIdList></Reference><Reference><Citation>Perfetti A., Greco S., Cardani R., Fossati B., Cuomo G., Valaperta R., Ambrogi F., Cortese A., Botta A., Mignarri A., et al. Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1. Sci. Rep. 2016;6:38174. doi: 10.1038/srep38174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38174</ArticleId><ArticleId IdType="pmc">PMC5131283</ArticleId><ArticleId IdType="pubmed">27905532</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegoraro V., Cudia P., Baba A., Angelini C. MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy. Neurol. Sci. 2020;41:2953&#x2013;2960. doi: 10.1007/s10072-020-04409-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04409-2</ArticleId><ArticleId IdType="pubmed">32350671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tymms K., Webb J. Dermatopolymyositis and other connective tissue diseases: A review of 105 cases. J. Rheumatol. 1985;12:1140&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">4093921</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluk H., Van Hoeve B.J.A., Van Dooren S.H.J., Stammen-Vogelzangs J., Van Der Heijden A., Schelhaas H.J., Verbeek M., Badrising U.A., Arnardottir S., Gheorghe K., et al. Autoantibodies to cytosolic 5&#x2032;-nucleotidase 1A in inclusion body myositis. Ann. Neurol. 2012;73:397&#x2013;407. doi: 10.1002/ana.23822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23822</ArticleId><ArticleId IdType="pubmed">23460448</ArticleId></ArticleIdList></Reference><Reference><Citation>Milone M. Diagnosis and Management of Immune-Mediated Myopathies. Mayo Clin. Proc. 2017;92:826&#x2013;837. doi: 10.1016/j.mayocp.2016.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2016.12.025</ArticleId><ArticleId IdType="pubmed">28473041</ArticleId></ArticleIdList></Reference><Reference><Citation>Palterer B., Vitiello G., Carraresi A., Giudizi M.G., Cammelli D., Parronchi P. Bench to bedside review of myositis autoantibodies. Clin. Mol. Allergy. 2018;16:1&#x2013;17. doi: 10.1186/s12948-018-0084-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12948-018-0084-9</ArticleId><ArticleId IdType="pmc">PMC5840827</ArticleId><ArticleId IdType="pubmed">29540998</ArticleId></ArticleIdList></Reference><Reference><Citation>Benveniste O., Goebel H.-H., Stenzel W. Biomarkers in Inflammatory Myopathies&#x2014;An Expanded Definition. Front. Neurol. 2019;10:554. doi: 10.3389/fneur.2019.00554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00554</ArticleId><ArticleId IdType="pmc">PMC6558048</ArticleId><ArticleId IdType="pubmed">31214105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchini M., Maggi L., Pegoraro E., Filosto M., Rodolico C., Antonini G., Garibaldi M., Valentino M., Siciliano G., Tasca G., et al. Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body Myositis. Cells. 2021;10:1146. doi: 10.3390/cells10051146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10051146</ArticleId><ArticleId IdType="pmc">PMC8151681</ArticleId><ArticleId IdType="pubmed">34068623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C., Feldman D., Stevens M.B. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin. Arthritis Rheum. 1986;15:168&#x2013;178. doi: 10.1016/0049-0172(86)90014-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(86)90014-4</ArticleId><ArticleId IdType="pubmed">3515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima Y., Uzawa A., Ozawa Y., Yasuda M., Onishi Y., Akamine H., Kawaguchi N., Himuro K., Noto Y.I., Mizuno T., et al. Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome. J. Neurol. Neurosurg. Psychiatry. 2021;92:963&#x2013;968. doi: 10.1136/jnnp-2020-325511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325511</ArticleId><ArticleId IdType="pubmed">33766920</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterhuis H., Limburg P.C., Hummel-Tappel E., The T.H. Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 2. Clinical and serological follow-up of individual patients. J. Neurol. Sci. 1983;58:371&#x2013;385. doi: 10.1016/0022-510X(83)90096-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(83)90096-5</ArticleId><ArticleId IdType="pubmed">6842265</ArticleId></ArticleIdList></Reference><Reference><Citation>McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 2004;55:580&#x2013;584. doi: 10.1002/ana.20061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20061</ArticleId><ArticleId IdType="pubmed">15048899</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D.B., El-Salem K., Massey J.M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978&#x2013;1980. doi: 10.1212/01.WNL.0000065882.63904.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000065882.63904.53</ArticleId><ArticleId IdType="pubmed">12821744</ArticleId></ArticleIdList></Reference><Reference><Citation>Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., Marino M., Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304&#x2013;2311. doi: 10.1093/brain/awg223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awg223</ArticleId><ArticleId IdType="pubmed">12821509</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoccioni E., Scuderi F., Minicuci G.M., Marino M., Ciaraffa F., Evoli A. Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology. 2006;67:505&#x2013;507. doi: 10.1212/01.wnl.0000228225.23349.5d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000228225.23349.5d</ArticleId><ArticleId IdType="pubmed">16894117</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandan R., Hehir M.K., Waheed W., Howard D.B. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve. 2017;56:185&#x2013;196. doi: 10.1002/mus.25597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25597</ArticleId><ArticleId IdType="pubmed">28164324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisimopoulou P., Evangelakou P., Tzartos J., Lazaridis K., Zouvelou V., Mantegazza R., Antozzi C., Andreetta F., Evoli A., Deymeer F., et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J. Autoimmun. 2014;52:139&#x2013;145. doi: 10.1016/j.jaut.2013.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2013.12.004</ArticleId><ArticleId IdType="pubmed">24373505</ArticleId></ArticleIdList></Reference><Reference><Citation>Romi F., Suzuki S., Suzuki N., Petzold A., Plant G.T., Gilhus N.E. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J. Neurol. 2012;259:1312&#x2013;1316. doi: 10.1007/s00415-011-6344-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6344-y</ArticleId><ArticleId IdType="pubmed">22167224</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley C., Newsom-Davis J., Willcox N., Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 2001;57:1579&#x2013;1582. doi: 10.1212/WNL.57.9.1579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.9.1579</ArticleId><ArticleId IdType="pubmed">11706095</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S., Baba A., Kaida K., Utsugisawa K., Kita Y., Tsugawa J., Ogawa G., Nagane Y., Kuwana M., Suzuki N. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur. J. Neurol. 2014;21:223&#x2013;230. doi: 10.1111/ene.12234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12234</ArticleId><ArticleId IdType="pubmed">23829303</ArticleId></ArticleIdList></Reference><Reference><Citation>Punga T., Le Panse R., Andersson M., Truffault F., Berrih-Aknin S., Punga A. Circulating mi RNA s in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann. Clin. Transl. Neurol. 2013;1:49&#x2013;58. doi: 10.1002/acn3.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.24</ArticleId><ArticleId IdType="pmc">PMC4207504</ArticleId><ArticleId IdType="pubmed">25356381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabre L., Maddison P., Wong S.H., Sadalage G., Ambrose P.A., Plant G.T., Punga A.R. miR-30e-5p as predictor of generalization in ocular myasthenia gravis. Ann. Clin. Transl. Neurol. 2019;6:243&#x2013;251. doi: 10.1002/acn3.692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.692</ArticleId><ArticleId IdType="pmc">PMC6389736</ArticleId><ArticleId IdType="pubmed">30847357</ArticleId></ArticleIdList></Reference><Reference><Citation>Punga A.R., Andersson M., Alimohammadi M., Punga T. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. J. Neurol. Sci. 2015;356:90&#x2013;96. doi: 10.1016/j.jns.2015.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.019</ArticleId><ArticleId IdType="pubmed">26095457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennon V.A., Kryzer T.J., Griesmann G.E., O&#x2019;Suilleabhain P.E., Windebank A.J., Woppmann A., Miljanich G.P., Lambert E.H. Calcium-Channel Antibodies in the Lambert&#x2013;Eaton Syndrome and Other Paraneoplastic Syndromes. New Engl. J. Med. 1995;332:1467&#x2013;1475. doi: 10.1056/NEJM199506013322203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199506013322203</ArticleId><ArticleId IdType="pubmed">7739683</ArticleId></ArticleIdList></Reference><Reference><Citation>Motomura M., Lang B., Johnston I., Palace J., Vincent A., Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 1997;147:35&#x2013;42. doi: 10.1016/S0022-510X(96)05303-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(96)05303-8</ArticleId><ArticleId IdType="pubmed">9094058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabater L., Titulaer M., Saiz A., Verschuuren J., Gure A.O., Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70:924&#x2013;928. doi: 10.1212/01.wnl.0000281663.81079.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000281663.81079.24</ArticleId><ArticleId IdType="pubmed">18032743</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddison P., Gozzard P., Sadalage G., Ambrose P.A., Chapman C.J., Murray A., Thomsen S., Berretta A., Lang B. Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome. J. Neuroimmunol. 2020;340:577149. doi: 10.1016/j.jneuroim.2020.577149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2020.577149</ArticleId><ArticleId IdType="pubmed">31951874</ArticleId></ArticleIdList></Reference><Reference><Citation>Titulaer M.J., Klooster R., Potman M., Sabater L., Graus F., Hegeman I.M., Thijssen P.E., Wirtz P.W., Twijnstra A., Smitt P.A.S., et al. SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation With Survival. J. Clin. Oncol. 2009;27:4260&#x2013;4267. doi: 10.1200/JCO.2008.20.6169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2008.20.6169</ArticleId><ArticleId IdType="pubmed">19667272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandelius &#xc5;., Zetterberg H., Blennow K., Adiutori R., Malaspina A., Laura M., Reilly M.M., Rossor A.M. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90:e518&#x2013;e524. doi: 10.1212/WNL.0000000000004932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004932</ArticleId><ArticleId IdType="pmc">PMC5818017</ArticleId><ArticleId IdType="pubmed">29321234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Davison M., Wang K., Xia T., Kramer M., Call K., Luo J., Wu X., Zuccarino R., Bacon C., et al. Transmembrane protease serine 5: A novel Schwann cell plasma marker for CMT1A. Ann. Clin. Transl. Neurol. 2020;7:69&#x2013;82. doi: 10.1002/acn3.50965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50965</ArticleId><ArticleId IdType="pmc">PMC6952315</ArticleId><ArticleId IdType="pubmed">31833243</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunami N., Smith B., Ballard L., Lensch M.W., Robertson M., Albertsen H., Hanemann C.O., M&#xfc;ller H.W., Bird T.D., White R., et al. Peripheral myelin protein&#x2013;22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot&#x2013;Marie&#x2013;Tooth 1A. Nat. Genet. 1992;1:176&#x2013;179. doi: 10.1038/ng0692-176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0692-176</ArticleId><ArticleId IdType="pubmed">1303231</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantera H., Shy M.E., Svaren J. Regulating PMP22 expression as a dosage sensitive neuropathy gene. Brain Res. 2020;1726:146491. doi: 10.1016/j.brainres.2019.146491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146491</ArticleId><ArticleId IdType="pmc">PMC7006452</ArticleId><ArticleId IdType="pubmed">31586623</ArticleId></ArticleIdList></Reference><Reference><Citation>Svaren J., Moran J.J., Wu X., Zuccarino R., Bacon C., Bai Y., Ramesh R., Gutmann L., Do D.M.A., Pavelec D., et al. Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies. Ann. Neurol. 2019;85:887&#x2013;898. doi: 10.1002/ana.25480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25480</ArticleId><ArticleId IdType="pmc">PMC7050273</ArticleId><ArticleId IdType="pubmed">30945774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Davison M., Wang K., Xia T.-H., Call K.M., Luo J., Wu X., Zuccarino R., Bacha A., Bai Y., et al. MicroRNAs as Biomarkers of Charcot-Marie-Tooth Disease Type 1A. Neurology. 2021;97:e489&#x2013;e500. doi: 10.1212/WNL.0000000000012266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012266</ArticleId><ArticleId IdType="pmc">PMC8356381</ArticleId><ArticleId IdType="pubmed">34031204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki N., Hartung H.-P. Guillain&#x2013;Barr&#xe9; Syndrome. New Engl. J. Med. 2012;366:2294&#x2013;2304. doi: 10.1056/NEJMra1114525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1114525</ArticleId><ArticleId IdType="pubmed">22694000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekiguchi Y., Uncini A., Yuki N., Misawa S., Notturno F., Nasu S., Kanai K., Noto Y.-I., Fujimaki Y., Shibuya K., et al. Antiganglioside antibodies are associated with axonal Guillain&#x2013;Barr&#xe9; syndrome: A Japanese&#x2013;Italian collaborative study. J. Neurol. Neurosurg. Psychiatry. 2012;83:23&#x2013;28. doi: 10.1136/jnnp-2011-300309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300309</ArticleId><ArticleId IdType="pubmed">22010183</ArticleId></ArticleIdList></Reference><Reference><Citation>Cats E.A., Jacobs B.C., Yuki N., Tio-Gillen A.P., Piepers S., Franssen H., Van Asseldonk J.-T., Berg L.H.V.D., Van Der Pol W.-L. Multifocal motor neuropathy: Association of anti-GM1 IgM antibodies with clinical features. Neurology. 2010;75:1961&#x2013;1967. doi: 10.1212/WNL.0b013e3181ff94c2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ff94c2</ArticleId><ArticleId IdType="pubmed">20962291</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagashima T., Koga M., Odaka M., Hirata K., Yuki N. Continuous Spectrum of Pharyngeal-Cervical-Brachial Variant of Guillain-Barr&#xe9; Syndrome. Arch. Neurol. 2007;64:1519&#x2013;1523. doi: 10.1001/archneur.64.10.1519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.10.1519</ArticleId><ArticleId IdType="pubmed">17923636</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobile-Orazio E., Manfredini E., Carpo M., Meucci N., Monaco S., Ferrari S., Bonetti B., Cavaletti G., Gemignani F., Durelli L., et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann. Neurol. 1994;36:416&#x2013;424. doi: 10.1002/ana.410360313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410360313</ArticleId><ArticleId IdType="pubmed">8080249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas M.C., Rakocevic G., Salajegheh M., Dambrosia J.M., Hahn A.F., Raju R., McElroy B. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann. Neurol. 2009;65:286&#x2013;293. doi: 10.1002/ana.21577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21577</ArticleId><ArticleId IdType="pubmed">19334068</ArticleId></ArticleIdList></Reference><Reference><Citation>Breville G., Lascano A.M., Roux-Lombard P., Vuilleumier N., Lalive P.H. Interleukin 8, a Biomarker to Differentiate Guillain-Barr&#xe9; Syndrome From CIDP. Neurol.-Neuroimmunol. Neuroinflammation. 2021;8:e1031. doi: 10.1212/NXI.0000000000001031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001031</ArticleId><ArticleId IdType="pmc">PMC8216426</ArticleId><ArticleId IdType="pubmed">34140310</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Aguilar L., Camps-Renom P., Lleix&#xe0; C., Pascual-Go&#xf1;i E., D&#xed;az-Manera J., Rojas-Garc&#xed;a R., De Luna N., Gallardo E., Cort&#xe9;s-Vicente E., Mu&#xf1;oz L., et al. Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr&#xe9; syndrome patients. J. Neurol. Neurosurg. Psychiatry. 2021;92:70&#x2013;77. doi: 10.1136/jnnp-2020-323899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323899</ArticleId><ArticleId IdType="pubmed">33154183</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiziano F.D., Pinto A.M., Fiori S., Lomastro R., Messina S., Bruno C., Pini A., Pane M., D&#x2019;Amico A., Ghezzo A., et al. SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur. J. Hum. Genet. 2010;18:52&#x2013;58. doi: 10.1038/ejhg.2009.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2009.116</ArticleId><ArticleId IdType="pmc">PMC2987170</ArticleId><ArticleId IdType="pubmed">19603064</ArticleId></ArticleIdList></Reference><Reference><Citation>Brichta L., H&#xf6;lker I., Haug K., Klockgether T., Wirth B. In vivo activation ofSMNin spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 2006;59:970&#x2013;975. doi: 10.1002/ana.20836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20836</ArticleId><ArticleId IdType="pubmed">16607616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner C.J., Kolb S.J., Harmison G.G., Jeffries N.O., Schadt K., Finkel R.S., Dreyfuss G., Fischbeck K.H. SMN mRNA and protein levels in peripheral blood. Neurology. 2006;66:1067&#x2013;1073. doi: 10.1212/01.wnl.0000201929.56928.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000201929.56928.13</ArticleId><ArticleId IdType="pubmed">16481599</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier A., Weetall M., Heinig K., Bucheli F., Schoenlein K., Alsenz J., Bassett S., Ullah M., Senn C., Ratni H., et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol. Res. Perspect. 2018;6:e00447. doi: 10.1002/prp2.447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.447</ArticleId><ArticleId IdType="pmc">PMC6262736</ArticleId><ArticleId IdType="pubmed">30519476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiziano F.D., Lomastro R., Abiusi E., Pasanisi M.B., Di Pietro L., Fiori S., Baranello G., Angelini C., Sorar&#xf9; G., Gaiani A., et al. Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: Results of a phase IIb double-blind study of salbutamol. J. Med Genet. 2019;56:293&#x2013;300. doi: 10.1136/jmedgenet-2018-105482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2018-105482</ArticleId><ArticleId IdType="pubmed">30593463</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras B.T., Crawford T.O., Finkel R.S., Mercuri E., De Vivo D.C., Oskoui M., Tizzano E.F., Ryan M.M., Muntoni F., Zhao G., et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 2019;6:932&#x2013;944. doi: 10.1002/acn3.779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.779</ArticleId><ArticleId IdType="pmc">PMC6530526</ArticleId><ArticleId IdType="pubmed">31139691</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B., Alberg L., Cullen N.C., Michael E., Wahlgren L., Kroksmark A.-K., Rostasy K., Blennow K., Zetterberg H., Tulinius M. NFL is a marker of treatment response in children with SMA treated with nusinersen. J. Neurol. 2019;266:2129&#x2013;2136. doi: 10.1007/s00415-019-09389-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09389-8</ArticleId><ArticleId IdType="pmc">PMC6687695</ArticleId><ArticleId IdType="pubmed">31123861</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves C.R., Zhang R., Johnstone A.J., Garner R., Nwe P.H., Siranosian J.J., Swoboda K.J. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology. 2020;94:e921&#x2013;e931. doi: 10.1212/WNL.0000000000008762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008762</ArticleId><ArticleId IdType="pmc">PMC7238944</ArticleId><ArticleId IdType="pubmed">31882526</ArticleId></ArticleIdList></Reference><Reference><Citation>Catapano F., Zaharieva I., Scoto M., Marrosu E., Morgan J., Muntoni F., Zhou H. Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy. Mol. Ther.-Nucleic Acids. 2016;5:e331. doi: 10.1038/mtna.2016.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2016.47</ArticleId><ArticleId IdType="pmc">PMC5014531</ArticleId><ArticleId IdType="pubmed">27377135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanno S., Marcuzzo S., Malacarne C., Giagnorio E., Masson R., Zanin R., Arnoldi M.T., Andreetta F., Simoncini O., Venerando A., et al. Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. Biomedicines. 2020;8:21. doi: 10.3390/biomedicines8020021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8020021</ArticleId><ArticleId IdType="pmc">PMC7168147</ArticleId><ArticleId IdType="pubmed">31991852</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichelberger E.J., Alves C.R.R., Zhang R., Petrillo M., Cullen P., Farwell W., Hurt J.A., Staropoli J.F., Swoboda K.J. Increased systemic HSP70B levels in spinal muscular atrophy infants. Ann. Clin. Transl. Neurol. 2021;8:1495&#x2013;1501. doi: 10.1002/acn3.51377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51377</ArticleId><ArticleId IdType="pmc">PMC8283166</ArticleId><ArticleId IdType="pubmed">33991176</ArticleId></ArticleIdList></Reference><Reference><Citation>Introna A., Milella G., D&#x2019;Errico E., Fraddosio A., Scaglione G., Ucci M., Bsc M.R., Simone I.L. Is cerebrospinal fluid amyloid-&#x3b2;42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? Muscle Nerve. 2021;63:905&#x2013;909. doi: 10.1002/mus.27212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27212</ArticleId><ArticleId IdType="pmc">PMC8251706</ArticleId><ArticleId IdType="pubmed">33660868</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K., De Schaepdryver M., Stubendorff B., Gille B., Muckova P., Wendler S., Prell T., Ringer T.M., Rhode H., Stevens O., et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302&#x2013;2309. doi: 10.1212/WNL.0000000000004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Henderson R.D., David M., McCombe P.A. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11:e0164625. doi: 10.1371/journal.pone.0164625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164625</ArticleId><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Lombardi V., Jeromin A., Bowser R., Andersen P.M., Malaspina A. Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph. Lateral Scler. Front. Degener. 2019;20:538&#x2013;548. doi: 10.1080/21678421.2019.1646769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Huss A., Mayer B., Grehl T., Grosskreutz J., Borck G., Kuhle J., Lul&#xe9; D., Meyer T., Oeckl P., et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotroph. Lateral Scler. Front. Degener. 2017;18:112&#x2013;119. doi: 10.1080/21678421.2016.1241279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1241279</ArticleId><ArticleId IdType="pubmed">27819158</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P., Oeckl P., Huss A., M&#xfc;ller K., Volk A.E., Kuhle J., Knehr A., Andersen P.M., Prudlo J., Steinacker P., et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 2016;79:152&#x2013;158. doi: 10.1002/ana.24552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P., Feneberg E., Weishaupt J., Brettschneider J., Tumani H., Andersen P.M., Von Arnim C.A.F., B&#xf6;hm S., Kassubek J., Kubisch C., et al. Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry. 2016;87:12&#x2013;20. doi: 10.1136/jnnp-2015-311387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D., Volanti P., Brambilla L., Colletti T., Spataro R., La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J. Neurol. 2018;265:510&#x2013;521. doi: 10.1007/s00415-017-8730-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R., Copetti M., Panza F., Cortese R., Capozzo R., D&#x2019;Errico E., Fontana A., Simone I.L., Logroscino G. Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis: Table 1. J. Neurol. Neurosurg. Psychiatry. 2016;87:678&#x2013;679. doi: 10.1136/jnnp-2014-308478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308478</ArticleId><ArticleId IdType="pubmed">25995485</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Goossens J., Dedeene L., De Vocht J., Oldoni E., Goris A., Bosch L.V.D., Depreitere B., Claeys K.G., et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol. Appl. Neurobiol. 2019;45:291&#x2013;304. doi: 10.1111/nan.12511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E., Demattei C., Lehmann S., Maceski-Maleska A., Hirtz C., Juntas-Morales R., Pageot N., Esselin F., Alphand&#xe9;ry S., Vincent T., et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur. J. Neurol. 2020;27:251&#x2013;257. doi: 10.1111/ene.14063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14063</ArticleId><ArticleId IdType="pubmed">31437330</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone Y.M., Domi T., Agosta F., Pozzi L., Schito P., Fazio R., Del Carro U., Barbieri A., Comola M., Leocani L., et al. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J. Neurol. 2020;267:2272&#x2013;2280. doi: 10.1007/s00415-020-09838-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09838-9</ArticleId><ArticleId IdType="pmc">PMC7166001</ArticleId><ArticleId IdType="pubmed">32306171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C., Oeckl P., Weishaupt J.H., Volk A.E., Diehl-Schmid J., Schroeter M.L., Lauer M., Kornhuber J., Levin J., Fassbender K., et al. Poly- GP in cerebrospinal fluid links C9orf72 -associated dipeptide repeat expression to the asymptomatic phase of ALS / FTD. EMBO Mol. Med. 2017;9:859&#x2013;868. doi: 10.15252/emmm.201607486.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607486</ArticleId><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Bs L.M.D., Ms M.G.H., Bs N.N.D., ScM J.W., Miller T.M., Pastor P., Trojanowski J.Q., Grossman M., Berry M.J.D., et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF 72 -associated amyotrophic lateral sclerosis. Ann. Neurol. 2017;82:139&#x2013;146. doi: 10.1002/ana.24980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourbouli M., Rentzos M., Bougea A., Zouvelou V., Constantinides V.C., Zaganas I., Evdokimidis I., Kapaki E., Paraskevas G.P. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. Dement. Geriatr. Cogn. Disord. 2017;44:144&#x2013;152. doi: 10.1159/000478979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000478979</ArticleId><ArticleId IdType="pubmed">28848086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong M.-L., Tan P.F., Holbrook J.D. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS ONE. 2017;12:e0174925. doi: 10.1371/journal.pone.0174925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pmc">PMC5390993</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq M.K., Lee E., Bradburn M., McDermott C.J., Shaw P.J. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:1071&#x2013;1078. doi: 10.1111/ene.12995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12995</ArticleId><ArticleId IdType="pubmed">27029589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Hergesheimer R.C., Bakkouche S.E., Beltran S., Vourc&#x2019;H P., Andres C.R., Dufour-Rainfray D., Corcia P., Blasco H. A&#x3b2;1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2020;21:2911. doi: 10.3390/ijms21082911.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21082911</ArticleId><ArticleId IdType="pmc">PMC7216266</ArticleId><ArticleId IdType="pubmed">32326346</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange D.J., Shahbazi M., Silani V., Ludolph A.C., Weishaupt J.H., Ajroud-Driss S., Fields K.G., Remanan R., Appel S.H., Morelli C., et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann. Neurol. 2017;81:837&#x2013;848. doi: 10.1002/ana.24950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24950</ArticleId><ArticleId IdType="pmc">PMC5518287</ArticleId><ArticleId IdType="pubmed">28480639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange D.J., Andersen P.M., Remanan R., Marklund S., Benjamin D. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study. Amyotroph. Lateral Scler. Front. Degener. 2013;14:199&#x2013;204. doi: 10.3109/17482968.2012.724074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.724074</ArticleId><ArticleId IdType="pubmed">22985433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravnik-Glava&#x10d; M., Glava&#x10d; D. Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2020;21:1714. doi: 10.3390/ijms21051714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21051714</ArticleId><ArticleId IdType="pmc">PMC7084402</ArticleId><ArticleId IdType="pubmed">32138249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinerman K.S., Toledo J.B., Tsivinsky V.G., Irwin D., Grossman M., Weintraub D., Hurtig H.I., Chen-Plotkin A., Wolk D.A., McCluskey L.F., et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer&#x2019;s Res. Ther. 2017;9:1&#x2013;13. doi: 10.1186/s13195-017-0316-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0316-0</ArticleId><ArticleId IdType="pmc">PMC5679501</ArticleId><ArticleId IdType="pubmed">29121998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Martone J., Lepore E., Casola I., Petrucci A., Inghilleri M., Morlando M., Colantoni A., Scicchitano B.M., Calvo A., et al. A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discov. 2021;7:1&#x2013;11. doi: 10.1038/s41420-020-00397-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-020-00397-6</ArticleId><ArticleId IdType="pmc">PMC7801652</ArticleId><ArticleId IdType="pubmed">33431881</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish M.J., Kenyon G.L. Relating Structure to Mechanism in Creatine Kinase. Crit. Rev. Biochem. Mol. Biol. 2005;40:1&#x2013;20. doi: 10.1080/10409230590918577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10409230590918577</ArticleId><ArticleId IdType="pubmed">15804623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang H., W&#xfc;rzburg U. Creatine kinase, an enzyme of many forms. Clin. Chem. 1982;28:1439&#x2013;1447. doi: 10.1093/clinchem/28.7.1439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/28.7.1439</ArticleId><ArticleId IdType="pubmed">7044614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty T., Tirupathi S., Thompson A. How to use: Creatine kinase. Arch. Dis. Child. Educ. Pr. Ed. 2020;105:157&#x2013;163. doi: 10.1136/archdischild-2019-317184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2019-317184</ArticleId><ArticleId IdType="pubmed">31296557</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson M.J., Round J.M., Newham D.J., Edwards R.H.T. An examination of some factors influencing creatine kinase in the blood of patients with muscular dystrophy. Muscle Nerve. 1987;10:15&#x2013;21. doi: 10.1002/mus.880100105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880100105</ArticleId><ArticleId IdType="pubmed">3561434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou L., Jiao B., Xiao T., Zhou L., Zhou Z., Du J., Yan X., Wang J., Tang B., Shen L. Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China. Sci. Rep. 2016;6:32478. doi: 10.1038/srep32478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep32478</ArticleId><ArticleId IdType="pmc">PMC5015023</ArticleId><ArticleId IdType="pubmed">27604643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H., Cui L., Guan Y., Liu M., Li X., Shen D., Li D., Cui B., Fang J., Ding Q., et al. Correlation of Creatine Kinase Levels with Clinical Features and Survival in Amyotrophic Lateral Sclerosis. Front. Neurol. 2017;8:322. doi: 10.3389/fneur.2017.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00322</ArticleId><ArticleId IdType="pmc">PMC5494475</ArticleId><ArticleId IdType="pubmed">28717355</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinaki M., Mulder D.W. Amyotrophic lateral sclerosis: Relationship between serum creatine kinase level and patient survival. Arch. Phys. Med. Rehabil. 1986;67:169&#x2013;171. doi: 10.1016/0003-9993(86)90064-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-9993(86)90064-X</ArticleId><ArticleId IdType="pubmed">3954579</ArticleId></ArticleIdList></Reference><Reference><Citation>Felice K.J., North W.A. Creatine kinase values in amyotrophic lateral sclerosis. J. Neurol. Sci. 1998;160:S30&#x2013;S32. doi: 10.1016/S0022-510X(98)00195-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00195-6</ArticleId><ArticleId IdType="pubmed">9851645</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandilands E.A., Dhaun N., Dear J.W., Webb D.J. Measurement of renal function in patients with chronic kidney disease. Br. J. Clin. Pharmacol. 2013;76:504&#x2013;515. doi: 10.1111/bcp.12198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12198</ArticleId><ArticleId IdType="pmc">PMC3791974</ArticleId><ArticleId IdType="pubmed">23802624</ArticleId></ArticleIdList></Reference><Reference><Citation>Szunyogova E., Zhou H., Maxwell G.K., Powis R.A., Muntoni F., Gillingwater T.H., Parson S.H. Survival Motor Neuron (SMN) protein is required for normal mouse liver development. Sci. Rep. 2016;6:34635. doi: 10.1038/srep34635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep34635</ArticleId><ArticleId IdType="pmc">PMC5048144</ArticleId><ArticleId IdType="pubmed">27698380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nery F.C., Siranosian J.J., Rosales I., Deguise M.-O., Sharma A., Muhtaseb A.W., Nwe P., Johnstone A.J., Zhang R., Fatouraei M., et al. Impaired kidney structure and function in spinal muscular atrophy. Neurol. Genet. 2019;5:e353. doi: 10.1212/NXG.0000000000000353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000353</ArticleId><ArticleId IdType="pmc">PMC6705648</ArticleId><ArticleId IdType="pubmed">31517062</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk R.P.A., Eijkemans M.J.C., Ferguson T.A., Nikolakopoulos S., Veldink J.H., Berg L.H.V.D. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry. 2018;89:156&#x2013;161. doi: 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Targoff I.N. Idiopathic inflammatory myopathy: Autoantibody update. Curr. Rheumatol. Rep. 2002;4:434&#x2013;441. doi: 10.1007/s11926-002-0089-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-002-0089-7</ArticleId><ArticleId IdType="pubmed">12217249</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S.A. Cytoplasmic 5&#x2032;-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve. 2014;50:488&#x2013;492. doi: 10.1002/mus.24199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24199</ArticleId><ArticleId IdType="pubmed">24752512</ArticleId></ArticleIdList></Reference><Reference><Citation>Limaye V.S., Lester S., Blumbergs P., Greenberg S.A. Anti- C N1A antibodies in South Australian patients with inclusion body myositis. Muscle Nerve. 2016;53:654&#x2013;655. doi: 10.1002/mus.24989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24989</ArticleId><ArticleId IdType="pubmed">26599102</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert M.K., Stammen-Vogelzangs J., Verbeek M.M., Rietveld A., Lundberg I.E., Chinoy H., Lamb J.A., Cooper R.G., Roberts M., Badrising U., et al. Disease specificity of autoantibodies to cytosolic 5&#x2032;-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann. Rheum. Dis. 2016;75:696&#x2013;701. doi: 10.1136/annrheumdis-2014-206691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206691</ArticleId><ArticleId IdType="pmc">PMC4699257</ArticleId><ArticleId IdType="pubmed">25714931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd T.E., Christopher-Stine L., Pinal-Fernandez I., Tiniakou E., Petri M., Baer A., Danoff S.K., Pak K., Casciola-Rosen L.A., Mammen A.L. Cytosolic 5&#x2032;-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Rheum. 2016;68:66&#x2013;71. doi: 10.1002/acr.22600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22600</ArticleId><ArticleId IdType="pmc">PMC4887848</ArticleId><ArticleId IdType="pubmed">25892010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilhus N.E., Skeie G.O., Romi N.E.G.G.O.S.F., Lazaridis K., Zisimopoulou P., Tzartos K.L.P.Z.S. Myasthenia gravis&#x2014;Autoantibody characteristics and their implications for therapy. Nat. Rev. Neurol. 2016;12:259&#x2013;268. doi: 10.1038/nrneurol.2016.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.44</ArticleId><ArticleId IdType="pubmed">27103470</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul. Disord. 2006;16:459&#x2013;467. doi: 10.1016/j.nmd.2006.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2006.05.006</ArticleId><ArticleId IdType="pubmed">16793269</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilhus N.E., Tzartos S., Evoli A., Palace J., Burns T.M., Verschuuren J.G.M. Myasthenia gravis. Nat. Rev. Dis. Prim. 2019;5:30. doi: 10.1038/s41572-019-0079-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0079-y</ArticleId><ArticleId IdType="pubmed">31048702</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., Beeson D., Willcox N., Vincent A. IgG1 antibodies to acetylcholine receptors in &#x2018;seronegative&#x2019; myasthenia gravis&#x2020;. Brain. 2008;131:1940&#x2013;1952. doi: 10.1093/brain/awn092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn092</ArticleId><ArticleId IdType="pmc">PMC2442426</ArticleId><ArticleId IdType="pubmed">18515870</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman D.B., Adams R.N., Josifek L.F., Self S.G. Functional Activities of Autoantibodies to Acetylcholine Receptors and the Clinical Severity of Myasthenia Gravis. New Engl. J. Med. 1982;307:769&#x2013;775. doi: 10.1056/NEJM198209233071301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198209233071301</ArticleId><ArticleId IdType="pubmed">7110241</ArticleId></ArticleIdList></Reference><Reference><Citation>Romi F., Skeie G.O., Aarli J.A., Gilhus N.E. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch. Neurol. 2000;57:1596&#x2013;1600. doi: 10.1001/archneur.57.11.1596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.11.1596</ArticleId><ArticleId IdType="pubmed">11074791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski H.J., Kusner L.L., Wolfe G.I., Aban I., Minisman G., Conwit R., Cutter G. Biomarker development for myasthenia gravis. Ann. New York Acad. Sci. 2012;1275:101&#x2013;106. doi: 10.1111/j.1749-6632.2012.06787.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2012.06787.x</ArticleId><ArticleId IdType="pmc">PMC3539232</ArticleId><ArticleId IdType="pubmed">23278584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun. Rev. 2013;12:924&#x2013;930. doi: 10.1016/j.autrev.2013.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.03.002</ArticleId><ArticleId IdType="pubmed">23537507</ArticleId></ArticleIdList></Reference><Reference><Citation>Koneczny I., Cossins J., Waters P., Beeson D., Vincent A. MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE. 2013;8:e80695. doi: 10.1371/journal.pone.0080695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0080695</ArticleId><ArticleId IdType="pmc">PMC3820634</ArticleId><ArticleId IdType="pubmed">24244707</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzartos J.S., Zisimopoulou P., Rentzos M., Karandreas N., Zouvelou V., Evangelakou P., Tsonis A., Thomaidis T., Lauria G., Andreetta F., et al. LRP 4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann. Clin. Transl. Neurol. 2014;1:80&#x2013;87. doi: 10.1002/acn3.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.26</ArticleId><ArticleId IdType="pmc">PMC4212481</ArticleId><ArticleId IdType="pubmed">25356387</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivner M.H., Liu S., Quarles B., Fleenor B., Shen C., Pan J., Mei L. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve. 2017;55:430&#x2013;432. doi: 10.1002/mus.25438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25438</ArticleId><ArticleId IdType="pmc">PMC5318258</ArticleId><ArticleId IdType="pubmed">27756107</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasperi C., Melms A., Schoser B., Zhang Y., Meltoranta J., Risson V., Schaeffer L., Schalke B., Kroger S. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82:1976&#x2013;1983. doi: 10.1212/WNL.0000000000000478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000478</ArticleId><ArticleId IdType="pubmed">24793185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Shen C., Bealmear B., Ragheb S., Xiong W.-C., Lewis R.A., Lisak R.P., Mei L. Autoantibodies to Agrin in Myasthenia Gravis Patients. PLoS ONE. 2014;9:e91816. doi: 10.1371/journal.pone.0091816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0091816</ArticleId><ArticleId IdType="pmc">PMC3954737</ArticleId><ArticleId IdType="pubmed">24632822</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo E., Martinez-Hernandez E., Titulaer M., Huijbers M.G., Mart&#xed;nez M.A., Ramos-Fransi A., Querol L., Diaz-Manera J., Rojas-Garc&#xed;a R., Hayworth C.R., et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun. Rev. 2014;13:1003&#x2013;1007. doi: 10.1016/j.autrev.2014.08.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.08.039</ArticleId><ArticleId IdType="pubmed">25193850</ArticleId></ArticleIdList></Reference><Reference><Citation>Labrador-Horrillo M., Mart&#xed;nez M.&#xc1;., Selva-O&#x2019;Callaghan A., Trallero-Aragu&#xe1;s E., Grau-Junyent J.M., Vilardell-Tarr&#xe9;s M., Ju&#xe1;rez C. Identification of a novel myositis-associated antibody directed against cortactin. Autoimmun. Rev. 2014;13:1008&#x2013;1012. doi: 10.1016/j.autrev.2014.08.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.08.038</ArticleId><ArticleId IdType="pubmed">25182205</ArticleId></ArticleIdList></Reference><Reference><Citation>Katarzyna M.Z., Belaya K., Leite M., Patrick W., Vincent A., Beeson D. Collagen Q &#x2013; A potential target for autoantibodies in myasthenia gravis. J. Neurol. Sci. 2015;348:241&#x2013;244. doi: 10.1016/j.jns.2014.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2014.12.015</ArticleId><ArticleId IdType="pmc">PMC6044427</ArticleId><ArticleId IdType="pubmed">25577314</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002;59:764&#x2013;766. doi: 10.1212/WNL.59.5.764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.5.764</ArticleId><ArticleId IdType="pubmed">12221175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccarato M., Gastaldi M., Zuliani L., Biagioli T., Brogi M., Bernardi G., Corsini E., Bazzigaluppi E., Fazio R., Giannotta C., et al. Diagnostics of paraneoplastic neurological syndromes. Neurol. Sci. 2017;38:237&#x2013;242. doi: 10.1007/s10072-017-3031-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3031-5</ArticleId><ArticleId IdType="pubmed">29030766</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuliani L., Zoccarato M., Gastaldi M., Iorio R., Evoli A., Biagioli T., Casagrande S., Bazzigaluppi E., Fazio R., Giannotta C., et al. Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens. Neurol. Sci. 2017;38:225&#x2013;229. doi: 10.1007/s10072-017-3032-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3032-4</ArticleId><ArticleId IdType="pubmed">29030767</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: Clinical and immunohistochemical studies. Neurology. 1993;43:1911. doi: 10.1212/WNL.43.10.1911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.10.1911</ArticleId><ArticleId IdType="pubmed">8413947</ArticleId></ArticleIdList></Reference><Reference><Citation>Franciotta D., Gastaldi M., Benedetti L., Pesce G., Biagioli T., Lolli F., Costa G., Melis C., Andreetta F., Simoncini O., et al. Diagnostics of dysimmune peripheral neuropathies. Neurol. Sci. 2017;38:243&#x2013;247. doi: 10.1007/s10072-017-3025-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3025-3</ArticleId><ArticleId IdType="pubmed">29030769</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamada Y., Hirano M., Kuwahara M., Samukawa M., Takada K., Morise J., Yabuno K., Oka S., Kusunoki S. Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy: Possible clinical relevance. Neurosci. Res. 2015;91:63&#x2013;68. doi: 10.1016/j.neures.2014.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2014.09.010</ArticleId><ArticleId IdType="pubmed">25450311</ArticleId></ArticleIdList></Reference><Reference><Citation>Planche V., Arnaud L., Viala K., Hospital M.A., Miyara M., Leger J.M., Neil J., Leblond V., Musset L. Heavy/Light Chain Ratio as a Biomarker for Monitoring Patients with IgM Monoclonal Gammopathy and Anti-MAG Neuropathy. J. Hematol. Thromboembolic Dis. 2014;2:142. doi: 10.4172/2329-8790.1000142.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2329-8790.1000142</ArticleId></ArticleIdList></Reference><Reference><Citation>Liem R.K., Yen S.H., Salomon G.D., Shelanski M.L. Intermediate filaments in nervous tissues. J. Cell Biol. 1978;79:637&#x2013;645. doi: 10.1083/jcb.79.3.637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.79.3.637</ArticleId><ArticleId IdType="pmc">PMC2110269</ArticleId><ArticleId IdType="pubmed">83322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman P.N., Cleveland D.W., Griffin J.W., Landes P.W., Cowan N.J., Price D.L. Neurofilament gene expression: A major determinant of axonal caliber. Proc. Natl. Acad. Sci. 1987;84:3472&#x2013;3476. doi: 10.1073/pnas.84.10.3472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.84.10.3472</ArticleId><ArticleId IdType="pmc">PMC304893</ArticleId><ArticleId IdType="pubmed">3472217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R.A., Shea T.B. Views and reviews dynamics of neuronal intermediate filaments: A developmental perspective. Cell Motil Cytoskeleton. 1992;22:81&#x2013;91. doi: 10.1002/cm.970220202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cm.970220202</ArticleId><ArticleId IdType="pubmed">1633625</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale J.M., Garcia M.L. Neurofilament Phosphorylation during Development and Disease: Which Came First, the Phosphorylation or the Accumulation? J. Amino Acids. 2012;2012:1&#x2013;10. doi: 10.1155/2012/382107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/382107</ArticleId><ArticleId IdType="pmc">PMC3337605</ArticleId><ArticleId IdType="pubmed">22570767</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrot R., Berges R., Bocquet A., Eyer J. Review of the Multiple Aspects of Neurofilament Functions, and their Possible Contribution to Neurodegeneration. Mol. Neurobiol. 2008;38:27&#x2013;65. doi: 10.1007/s12035-008-8033-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-008-8033-0</ArticleId><ArticleId IdType="pubmed">18649148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y., Lee B.H., Yip W., Chou P., Yip B.-S. Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders. Curr. Pharm. Des. 2019;25:4560&#x2013;4569. doi: 10.2174/1381612825666191210154535.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612825666191210154535</ArticleId><ArticleId IdType="pubmed">31820696</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K., Van Damme P. Diagnostic and Prognostic Performance of Neurofilaments in ALS. Front. Neurol. 2019;9:1167. doi: 10.3389/fneur.2018.01167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Faravelli I., Meneri M., Saccomanno D., Velardo D., Abati E., Gagliardi D., Parente V., Petrozzi L., Ronchi D., Stocchetti N., et al. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients. J. Cell. Mol. Med. 2020;24:3034&#x2013;3039. doi: 10.1111/jcmm.14939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.14939</ArticleId><ArticleId IdType="pmc">PMC7077557</ArticleId><ArticleId IdType="pubmed">32032473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurster C.D., Steinacker P., G&#xfc;nther R., Koch J.C., Lingor P., Uzelac Z., Witzel S., Wollinsky K., Winter B., Osmanovic A., et al. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. J. Neurol. 2020;267:36&#x2013;44. doi: 10.1007/s00415-019-09547-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09547-y</ArticleId><ArticleId IdType="pubmed">31552549</ArticleId></ArticleIdList></Reference><Reference><Citation>Totzeck A., Stolte B., Kizina K., Bolz S., Schlag M., Thimm A., Kleinschnitz C., Hagenacker T. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen. Int. J. Mol. Sci. 2019;20:5397. doi: 10.3390/ijms20215397.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20215397</ArticleId><ArticleId IdType="pmc">PMC6862027</ArticleId><ArticleId IdType="pubmed">31671515</ArticleId></ArticleIdList></Reference><Reference><Citation>Spicer C., Lu C.-H., Catapano F., Scoto M., Zaharieva I., Malaspina A., Morgan J.E., Greensmith L., Muntoni F., Zhou H. The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy. Ann. Clin. Transl. Neurol. 2021;8:866&#x2013;876. doi: 10.1002/acn3.51336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51336</ArticleId><ArticleId IdType="pmc">PMC8045929</ArticleId><ArticleId IdType="pubmed">33683023</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren L.E., Karlsson J.-E., Karlsson J.-O., Persson L.I., Wikkels&#xf8; C. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF. J. Neurochem. 1996;67:2013&#x2013;2018. doi: 10.1046/j.1471-4159.1996.67052013.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67052013.x</ArticleId><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S., Vacchiano V., Zenesini C., Polischi B., de Pasqua S., Fileccia E., Mammana A., di Stasi V., Capellari S., Salvi F., et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 2020;267:1699&#x2013;1708. doi: 10.1007/s00415-020-09761-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09761-z</ArticleId><ArticleId IdType="pubmed">32100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D., Faravelli I., Meneri M., Saccomanno D., Govoni A., Magri F., Ricci G., Siciliano G., Comi G.P., Corti S. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: A cross-sectional study. J. Cell. Mol. Med. 2021;25:3765&#x2013;3771. doi: 10.1111/jcmm.16240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.16240</ArticleId><ArticleId IdType="pmc">PMC8051694</ArticleId><ArticleId IdType="pubmed">33609080</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke R.A.L., Gray E., Lu C.-H., Kuhle J., Talbot K., Malaspina A., Turner M.R. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann. Clin. Transl. Neurol. 2015;2:748&#x2013;755. doi: 10.1002/acn3.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.212</ArticleId><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A., Martinelli I., Bello L., Querin G., Puthenparampil M., Ruggero S., Toffanin E., Cagnin A., Briani C., Pegoraro E., et al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017;74:525&#x2013;532. doi: 10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Dreger M., Steinbach R., Gaur N., Metzner K., Stubendorff B., Witte O.W., Grosskreutz J. Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. Front. Neurosci. 2021;15:264. doi: 10.3389/fnins.2021.651651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.651651</ArticleId><ArticleId IdType="pmc">PMC8056017</ArticleId><ArticleId IdType="pubmed">33889072</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W. MicroRNAs: Biomarkers, Diagnostics, and Therapeutics. Methods Mol. Biol. 2017;1617:57&#x2013;67. doi: 10.1007/978-1-4939-7046-9_4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7046-9_4</ArticleId><ArticleId IdType="pubmed">28540676</ArticleId></ArticleIdList></Reference><Reference><Citation>Magri F., Vanoli F., Corti S. miRNA in spinal muscular atrophy pathogenesis and therapy. J. Cell. Mol. Med. 2017;22:755&#x2013;767. doi: 10.1111/jcmm.13450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13450</ArticleId><ArticleId IdType="pmc">PMC5783860</ArticleId><ArticleId IdType="pubmed">29160009</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswambharan V., Thanseem I., Vasu M.M., Poovathinal S.A., Anitha A. miRNAs as biomarkers of neurodegenerative disorders. Biomarkers Med. 2017;11:151&#x2013;167. doi: 10.2217/bmm-2016-0242.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2016-0242</ArticleId><ArticleId IdType="pubmed">28125293</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg I., Eran A., Nishino I., Moggio M., Lamperti C., Amato A.A., Lidov H.G., Kang P., North K.N., Mitrani-Rosenbaum S., et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc. Natl. Acad. Sci. 2007;104:17016&#x2013;17021. doi: 10.1073/pnas.0708115104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0708115104</ArticleId><ArticleId IdType="pmc">PMC2040449</ArticleId><ArticleId IdType="pubmed">17942673</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.-H., Chen J.-A. Multifaceted roles of microRNAs: From motor neuron generation in embryos to degeneration in spinal muscular atrophy. eLife. 2019;8 doi: 10.7554/eLife.50848.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.50848</ArticleId><ArticleId IdType="pmc">PMC6861003</ArticleId><ArticleId IdType="pubmed">31738166</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott B., Renshaw D., Getting S., MacKenzie R. The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol. 2012;205:324&#x2013;340. doi: 10.1111/j.1748-1716.2012.02423.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1748-1716.2012.02423.x</ArticleId><ArticleId IdType="pubmed">22340904</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirouche A., Jahnke V.E., Lunde J.A., Koulmann N., Freyssenet D.G., Jasmin B.J. Muscle-specific microRNA-206 targets multiple components in dystrophic skeletal muscle representing beneficial adaptations. Am. J. Physiol. Physiol. 2017;312:C209&#x2013;C221. doi: 10.1152/ajpcell.00185.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00185.2016</ArticleId><ArticleId IdType="pubmed">28003225</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., Williams A.H., Maxeiner J.M., Bezprozvannaya S., Shelton J.M., Richardson J.A., Bassel-Duby R., Olson E.N. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J. Clin. Investig. 2012;122:2054&#x2013;2065. doi: 10.1172/JCI62656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62656</ArticleId><ArticleId IdType="pmc">PMC3366415</ArticleId><ArticleId IdType="pubmed">22546853</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy J.J., Esser K.A., Andrade F.H. MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am. J. Physiol. Physiol. 2007;293:C451&#x2013;C457. doi: 10.1152/ajpcell.00077.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00077.2007</ArticleId><ArticleId IdType="pubmed">17459947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G., Wang Y., Li Y., Cui L., Zhao Y., Zhao B., Li K. MiR-206, a Key Modulator of Skeletal Muscle Development and Disease. Int. J. Biol. Sci. 2015;11:345&#x2013;352. doi: 10.7150/ijbs.10921.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.10921</ArticleId><ArticleId IdType="pmc">PMC4323374</ArticleId><ArticleId IdType="pubmed">25678853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci C., Marzocchi C., Battistini S. MicroRNAs as Biomarkers in Amyotrophic Lateral Sclerosis. Cells. 2018;7:219. doi: 10.3390/cells7110219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells7110219</ArticleId><ArticleId IdType="pmc">PMC6262636</ArticleId><ArticleId IdType="pubmed">30463376</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignier N., Amor F., Fogel P., Duvallet A., Poupiot J., Charrier S., Arock M., Montus M., Nelson I., Richard I., et al. Distinctive Serum miRNA Profile in Mouse Models of Striated Muscular Pathologies. PLoS ONE. 2013;8:e55281. doi: 10.1371/journal.pone.0055281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055281</ArticleId><ArticleId IdType="pmc">PMC3572119</ArticleId><ArticleId IdType="pubmed">23418438</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Kong M., Ye Y., Hong S., Cheng L., Jiang L. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. J. Neurochem. 2014;129:877&#x2013;883. doi: 10.1111/jnc.12662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12662</ArticleId><ArticleId IdType="pubmed">24460924</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaka Y., Kishi S., Aoki Y., Komaki H., Oya Y., Takeda S.-I., Hashido K. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ. Heal. Prev. Med. 2014;19:452&#x2013;458. doi: 10.1007/s12199-014-0405-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12199-014-0405-7</ArticleId><ArticleId IdType="pmc">PMC4235845</ArticleId><ArticleId IdType="pubmed">25150707</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Li Y., Zhao L., Zhang D., Yao X., Zhang H., Wang Y.-C., Wang X.-Y., Xia H., Yan J., et al. Circulating Muscle-specific miRNAs in Duchenne Muscular Dystrophy Patients. Mol. Ther. - Nucleic Acids. 2014;3:e177. doi: 10.1038/mtna.2014.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtna.2014.29</ArticleId><ArticleId IdType="pmc">PMC4121518</ArticleId><ArticleId IdType="pubmed">25050825</ArticleId></ArticleIdList></Reference><Reference><Citation>Molin C.J., Sabre L., Weis C.-A., Punga T., Punga A.R. Thymectomy lowers the myasthenia gravis biomarker miR-150-5p. Neurol.-Neuroimmunol. Neuroinflammation. 2018;5:e450. doi: 10.1212/NXI.0000000000000450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000450</ArticleId><ArticleId IdType="pmc">PMC5833334</ArticleId><ArticleId IdType="pubmed">29511707</ArticleId></ArticleIdList></Reference><Reference><Citation>Punga T., Bartoccioni E., Lewandowska M., Damato V., Evoli A., Punga A.R. Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis. J. Neuroimmunol. 2016;292:21&#x2013;26. doi: 10.1016/j.jneuroim.2016.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2016.01.003</ArticleId><ArticleId IdType="pubmed">26943954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L., Yu J.-T., Tan L. Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases. Mol. Neurobiol. 2015;51:1249&#x2013;1262. doi: 10.1007/s12035-014-8803-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8803-9</ArticleId><ArticleId IdType="pubmed">24973986</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z., Yunusova Y., Van Blitterswijk M., Dib S., Ghani M., Moreno D., Sato C., Liang Y., Singleton A., Robertson J., et al. Identical twins with the C9orf72 repeat expansion are discordant for ALS. Neurology. 2014;83:1476&#x2013;1478. doi: 10.1212/WNL.0000000000000886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000886</ArticleId><ArticleId IdType="pmc">PMC4206161</ArticleId><ArticleId IdType="pubmed">25209579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Xi Z., Ghani M., Jia P., Pal M., Werynska K., Moreno D., Sato C., Liang Y., Robertson J., et al. Genetic and epigenetic study of ALS-discordant identical twins with double mutations inSOD1andARHGEF28. J. Neurol. Neurosurg. Psychiatry. 2016;87:1268&#x2013;1270. doi: 10.1136/jnnp-2016-313592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313592</ArticleId><ArticleId IdType="pubmed">27154192</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., M&#xfc;ller K., Zondler L., Weydt P., Volk A.E., Bo&#x17e;i&#x10d; A.L., Walter M., Bonin M., Mayer B., Von Arnim C.A.F., et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014;137:2938&#x2013;2950. doi: 10.1093/brain/awu249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu249</ArticleId><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S.-W., Lopez-Anido C., MacArthur R., Svaren J., Inglese J. Identification of Drug Modulators Targeting Gene-Dosage Disease CMT1A. ACS Chem. Biol. 2012;7:1205&#x2013;1213. doi: 10.1021/cb300048d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cb300048d</ArticleId><ArticleId IdType="pmc">PMC3401360</ArticleId><ArticleId IdType="pubmed">22530759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis R.A. High-Dosage Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A. JAMA Neurol. 2013;70:981&#x2013;987. doi: 10.1001/jamaneurol.2013.3178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.3178</ArticleId><ArticleId IdType="pmc">PMC3752369</ArticleId><ArticleId IdType="pubmed">23797954</ArticleId></ArticleIdList></Reference><Reference><Citation>Katona I., Wu X., Feely S.M.E., Sottile S., Siskind C.E., Miller L.J., Shy M.E., Li J. PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain. 2009;132:1734&#x2013;1740. doi: 10.1093/brain/awp113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp113</ArticleId><ArticleId IdType="pmc">PMC2724915</ArticleId><ArticleId IdType="pubmed">19447823</ArticleId></ArticleIdList></Reference><Reference><Citation>Nobbio L., Visigalli D., Radice D., Fiorina E., Solari A., Lauria G., Reilly M.M., Santoro L., Schenone A., Pareyson D., et al. PMP22 messenger RNA levels in skin biopsies: Testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. Brain. 2014;137:1614&#x2013;1620. doi: 10.1093/brain/awu071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu071</ArticleId><ArticleId IdType="pubmed">24812204</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard L.R., B&#xe9;langer M.-C., Morissette S., Wride M., Prior T.W., Swoboda K. Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology. 2007;68:451&#x2013;456. doi: 10.1212/01.wnl.0000252934.70676.ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000252934.70676.ab</ArticleId><ArticleId IdType="pmc">PMC3273325</ArticleId><ArticleId IdType="pubmed">17283322</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezain M., Saugier-Veber P., Melki J., Toutain A., Bieth E., Husson M., Pedespan J.-M., Viollet L., Penisson-Besnier I., Fehrenbach S., et al. A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy. Eur. J. Hum. Genet. 2007;15:1054&#x2013;1062. doi: 10.1038/sj.ejhg.5201885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5201885</ArticleId><ArticleId IdType="pubmed">17609673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi D.T., Olson R.J., Sly L., Swanson C.J., Chung B., Naryshkin N., Narasimhan J., Bhattacharyya A., Mullenix M., Chen K.S. Utility of Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses. PLoS ONE. 2011;6:e24269. doi: 10.1371/journal.pone.0024269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024269</ArticleId><ArticleId IdType="pmc">PMC3164180</ArticleId><ArticleId IdType="pubmed">21904622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi D.T., Decker D., Zaworski P., Klott K., McGonigal J., Ghazal N., Sly L., Chung B., VanderLugt J., Chen K.S. Evaluation of Peripheral Blood Mononuclear Cell Processing and Analysis for Survival Motor Neuron Protein. PLoS ONE. 2012;7:e50763. doi: 10.1371/journal.pone.0050763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0050763</ArticleId><ArticleId IdType="pmc">PMC3511312</ArticleId><ArticleId IdType="pubmed">23226377</ArticleId></ArticleIdList></Reference><Reference><Citation>Czech C., Tang W., Bugawan T., Mano C., Horn C., Iglesias V.A., Fr&#xf6;hner S., Zaworski P.G., Paushkin S., Chen K., et al. Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls. PLoS ONE. 2015;10:e0139950. doi: 10.1371/journal.pone.0139950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0139950</ArticleId><ArticleId IdType="pmc">PMC4607439</ArticleId><ArticleId IdType="pubmed">26468953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jong Y.-J., Chang J.-G., Lin S.-P., Yang T.-Y., Wang J.-C., Chang C.-P., Lee C.-C., Li H., Hsieh-Li H.-M., Tsai C.-H. Analysis of the mRNA transcripts of the survival motor neuron (SMN) gene in the tissue of an SMA fetus and the peripheral blood mononuclear cells of normals, carriers and SMA patients. J. Neurol. Sci. 2000;173:147&#x2013;153. doi: 10.1016/S0022-510X(99)00325-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00325-1</ArticleId><ArticleId IdType="pubmed">10675659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb S.J., Coffey C.S., Yankey J.W., Krosschell K., Arnold W.D., Rutkove S.B., Swoboda K.J., Reyna S.P., Sakonju A., Darras B.T., et al. Baseline results of the Neuro NEXT spinal muscular atrophy infant biomarker study. Ann. Clin. Transl. Neurol. 2016;3:132&#x2013;145. doi: 10.1002/acn3.283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.283</ArticleId><ArticleId IdType="pmc">PMC4748311</ArticleId><ArticleId IdType="pubmed">26900585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C., Leoni E., Milani P., Pansarasa O., Mazzini G., Guareschi S., Alvisi E., Ghiroldi A., Diamanti L., Bernuzzi S., et al. Altered Intracellular Localization of SOD1 in Leukocytes from Patients with Sporadic Amyotrophic Lateral Sclerosis. PLoS ONE. 2013;8:e75916. doi: 10.1371/journal.pone.0075916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075916</ArticleId><ArticleId IdType="pmc">PMC3796534</ArticleId><ArticleId IdType="pubmed">24155874</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Walsh M.J., Higginbottom A., Highley J.R., Dickman M.J., Edbauer D., Ince P.G., Wharton S.B., Wilson S.A., Kirby J., et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain. 2014;137:2040&#x2013;2051. doi: 10.1093/brain/awu120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu120</ArticleId><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Z., Zhang Y., Gendron T.F., Bauer P.O., Chew J., Yang W.-Y., Fostvedt E., Jansen-West K., Belzil V.V., Desaro P., et al. Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron. 2014;83:1043&#x2013;1050. doi: 10.1016/j.neuron.2014.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.07.041</ArticleId><ArticleId IdType="pmc">PMC4232217</ArticleId><ArticleId IdType="pubmed">25132468</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T., Tokuda T., Ishigami N., Sasayama H., Foulds P., Mitchell D.J., Mann D.M.A., Allsop D., Nakagawa M. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2008;117:55&#x2013;62. doi: 10.1007/s00401-008-0456-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0456-1</ArticleId><ArticleId IdType="pubmed">18989684</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila A., Kuvaja M., Hartikainen P., Siloaho M., Helisalmi S., Moilanen V., Kiviharju A., Jansson L., Tienari P.J., Remes A.M., et al. Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. Dement. Geriatr. Cogn. Disord. Extra. 2016;6:142&#x2013;149. doi: 10.1159/000444788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000444788</ArticleId><ArticleId IdType="pmc">PMC4868946</ArticleId><ArticleId IdType="pubmed">27195002</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E., Steinacker P., Lehnert S., Schneider A., Walther P., Thal D., Linsenmeier M., Ludolph A.C., Otto M. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph. Lateral Scler. Front. Degener. 2014;15:351&#x2013;356. doi: 10.3109/21678421.2014.905606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.905606</ArticleId><ArticleId IdType="pubmed">24834468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha H., Debnath B., Neamati N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 2017;7:1543&#x2013;1588. doi: 10.7150/thno.15625.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.15625</ArticleId><ArticleId IdType="pmc">PMC5436513</ArticleId><ArticleId IdType="pubmed">28529637</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;gren M., Davidsson P., Wallin A., Gran&#xe9;rus A.-K., Grundstr&#xf6;m E., Askmark H., Vanmechelen E., Blennow K. Decreased CSF-&#x3b2;-Amyloid 42 in Alzheimer&#x2019;s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of &#x3b2;-Amyloid Induced by Disparate Mechanisms. Dement. Geriatr. Cogn. Disord. 2002;13:112&#x2013;118. doi: 10.1159/000048642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000048642</ArticleId><ArticleId IdType="pubmed">11844893</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P., Valentino F., Piccoli T., La Bella V., Piccoli F. Cerebrospinal fluidtauprotein is not a biological marker in amyotrophic lateral sclerosis. Eur. J. Neurol. 2009;16:257&#x2013;261. doi: 10.1111/j.1468-1331.2008.02405.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02405.x</ArticleId><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnert S., Costa J., De Carvalho M., Kirby J., Kuzma-Kozakiewicz M., Morelli C., Robberecht W., Shaw P., Silani V., Steinacker P., et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2014;15:344&#x2013;350. doi: 10.3109/21678421.2014.884592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.884592</ArticleId><ArticleId IdType="pubmed">24575871</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronson J.K. Biomarkers and surrogate endpoints. Br. J. Clin. Pharmacol. 2005;59:491&#x2013;494. doi: 10.1111/j.1365-2125.2005.02435.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2005.02435.x</ArticleId><ArticleId IdType="pmc">PMC1884846</ArticleId><ArticleId IdType="pubmed">15842546</ArticleId></ArticleIdList></Reference><Reference><Citation>Florence J.M., Fox P.T., Planer G.J., Brooke M.H. Activity, creatine kinase, and myoglobin in Duchenne muscular dystrophy: A clue to etiology? Neurology. 1985;35:758. doi: 10.1212/WNL.35.5.758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.35.5.758</ArticleId><ArticleId IdType="pubmed">4039424</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotton C., Passarelli C., Neri M., Ferlini A. Biomarkers in rare neuromuscular diseases. Exp. Cell Res. 2014;325:44&#x2013;49. doi: 10.1016/j.yexcr.2013.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2013.12.020</ArticleId><ArticleId IdType="pubmed">24389168</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus V.B., Blanco F.J., Englund M., Henrotin Y., Lohmander L.S., Losina E., Onnerfjord P., Persiani S. OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthr. Cartil. 2015;23:686&#x2013;697. doi: 10.1016/j.joca.2015.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2015.03.002</ArticleId><ArticleId IdType="pmc">PMC4430113</ArticleId><ArticleId IdType="pubmed">25952342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus V.B. Biomarkers as drug development tools: Discovery, validation, qualification and use. Nat. Rev. Rheumatol. 2018;14:354&#x2013;362. doi: 10.1038/s41584-018-0005-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0005-9</ArticleId><ArticleId IdType="pubmed">29760435</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBaer J. So, You Want to Look for Biomarkers (Introduction to the Special Biomarkers Issue) J. Proteome Res. 2005;4:1053&#x2013;1059. doi: 10.1021/pr0501259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr0501259</ArticleId><ArticleId IdType="pubmed">16083254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>